Johnson & Johnson Vision secures approval for Acuvue Oasys Max 1-Day

Johnson & Johnson Vision has completed CE Mark activities for the Acuvue Oasys MAX 1-Day and Acuvue Oasys MAX 1-Day Multifocal contact lenses.

The contact lenses have also received US Food and Drug Administration clearance and Health Canada approval.

The new contact lenses are designed to provide comfort and visual clarity throughout the day. The launch follows research that revealed 71% of eye care professionals see patients who are experiencing eye discomfort related to increased screen time, with young contact lens wearers spending an average of nine hours per day in front of a screen.

The premium range of contact lenses will be available in spherical and multifocal forms.

Peter Menziuso, company group chairman for Johnson & Johnson Vision, observed: “Our lives have evolved significantly over the past few years, creating increased demands on our eyes.”

With the launch of the new Acuvue Oasys Max 1-Day contact lenses, Menziuso said, “we look forward to bringing this solution to patients experiencing ever-demanding lifestyles and environments.”

The new lenses are expected to be available in the UK in autumn 2022, along with other European countries, the US, and Canada.